WallStSmart

Apyx Medical Inc (APYX)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 45102% more annual revenue ($25.27B vs $55.90M). SYK leads profitability with a 13.2% profit margin vs -16.4%. APYX appears more attractively valued with a PEG of 0.59. SYK earns a higher WallStSmart Score of 59/100 (C).

APYX

Hold

39

out of 100

Grade: F

Growth: 6.7Profit: 2.0Value: 7.7Quality: 4.5
Piotroski: 3/9Altman Z: -0.38

SYK

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

APYXUndervalued (+30.5%)

Margin of Safety

+30.5%

Fair Value

$5.64

Current Price

$4.47

$1.17 discount

UndervaluedFair: $5.64Overvalued
SYKSignificantly Overvalued (-35.2%)

Margin of Safety

-35.2%

Fair Value

$223.02

Current Price

$305.66

$82.64 premium

UndervaluedFair: $223.02Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APYX2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
32.5%10/10

Revenue surging 32.5% year-over-year

PEG RatioValuation
0.598/10

Growing faster than its price suggests

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$112.44B9/10

Large-cap with strong market position

Areas to Watch

APYX4 concerns · Avg: 3.5/10
Price/BookValuation
14.4x4/10

Trading at 14.4x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$165.82M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
33.9x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : APYX

The strongest argument for APYX centers on Revenue Growth, PEG Ratio. Revenue growth of 32.5% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bear Case : APYX

The primary concerns for APYX are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 3.08 is elevated, increasing financial risk.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

APYX profiles as a hypergrowth stock while SYK is a value play — different risk/reward profiles.

APYX carries more volatility with a beta of 1.35 — expect wider price swings.

APYX is growing revenue faster at 32.5% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Bottom Line

SYK scores higher overall (59/100 vs 39/100). APYX offers better value entry with a 30.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Apyx Medical Inc

HEALTHCARE · MEDICAL DEVICES · USA

Apyx Medical Corporation, an energy technology company, develops, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. The company is headquartered in Clearwater, Florida.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?